Australia · Delayed Price · Currency is AUD Imricor Medical Systems Earnings Call Transcripts
Fiscal Year 2026
-
The meeting reviewed significant clinical and regulatory milestones, highlighted a strengthened financial position, and approved key board elections, incentive plans, and auditor ratification. No questions were raised, and voting results will be released to the ASX.
Fiscal Year 2025
-
Major regulatory and clinical milestones achieved, including first-in-human MRI-guided VT ablation and FDA clearance for NorthStar. Revenue declined due to trial-related non-revenue procedures, but commercial readiness and pipeline growth position the company for significant expansion as approvals progress.
-
Revenue declined 52% year-over-year due to lower equipment sales, while net loss rose to $13.1 million, driven by fair value changes and increased investment in sales and R&D. Regulatory progress continues, with Northstar FDA approval and U.S. launch expected by year-end, and a strong cash position supports ongoing expansion.
-
The meeting covered global commercialization progress, new clinical applications, and recent financing that supports strategic growth. Key resolutions included director elections, equity plan approvals, and auditor ratification, with voting results to be released to the ASX.
-
MRI-guided cardiac ablation offers superior efficacy and cost savings over traditional X-ray methods, with strong clinical results and a $10 billion global market opportunity. Regulatory progress and a recent $70 million capital raise position the company for rapid global expansion and commercialization.
Fiscal Year 2024
-
Achieved 56% revenue growth in 2024, driven by new device approvals and expanding global commercialization. Anticipates major regulatory milestones and broader adoption in 2025, with Northstar and PFA programs as key growth drivers.
-
Shareholders voted on ratifying prior share issues and approving new placements in two tranches, with no questions raised. Voting results, representing 37.15% of issued capital, will be released to the ASX later today.
-
Revenue doubled year-over-year to $408,000, with net loss improving 26%. Regulatory and commercial milestones were achieved globally, and new capital raised is expected to fund operations into 2026. U.S. FDA trial and first MRI-guided VT ablation are key near-term catalysts.